Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ESDXP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Vorsetuzumab |
|||||
| Organization | Seagen Inc. |
|||||
| Indication | Inflammation; Autoimmune diseases |
|||||
| Synonyms |
h1F6; SGN-70; H-1F6
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | CD70 antigen (CD70) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTY
ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTY
ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTNYG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
INTYTGEP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
ARDYGDYGMDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLES
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLES
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSVSTSGYSF
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
LAS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QHSREVPWT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Vorsetuzumab mafodotin [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
58%
|
|||
| Patients Enrolled |
Eligible participants require confirmed NHL/RCC with CD70+ status, ≥1 prior systemic therapy failure, measurable lesions (NHL>1.5cm/RCC≥10mm). Key exclusions are prior allogeneic transplant, active secondary malignancy (<3y remission), or previous anti-CD70 therapy.
|
||||
| Administration Dosage |
SGN-75 was administered as an intravenous (IV) infusion without premedication every 3 weeks (Q3Wk), or on Days 1, 8, and 15 of 28-day cycles (weekly). Dose levels assessed were 0.3, 1.0, 1.5, 2.0, 3.0, and 4.5 mg/kg administered Q3Wk and 0.3 and 0.6 mg/kg administered weekly.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01015911 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
|
||||
| Primary Endpoint |
The study evaluates adverse events and lab abnormalities as primary safety outcomes, monitored until 1 month post-treatment.
|
||||
| Other Endpoint |
Secondary objectives include clinical response (assessed every 2 months), duration parameters (every 3 months), pharmacokinetics of SGN-75, and immunogenicity (both tracked through 1 month post-treatment).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients must have CD70+ metastatic renal cell carcinoma with ≥1 prior TKI, measurable disease, ECOG 0-1, and adequate organ function. Exclusions involve prior anti-CD70 therapy or >1 mTOR inhibitor regimen.
|
||||
| Administration Dosage |
1-2 mg/kg IV every 21 days
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01677390 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
|
||||
| Primary Endpoint |
The primary outcome measures include incidence of adverse events and lab abnormalities assessed up to 1 month post last dose, with clinical response evaluated per RECIST 1.1.
|
||||
| Other Endpoint |
Secondary endpoints cover progression-free survival (expected ~6 months), overall survival (expected ~1 year), SGN-75/metabolite blood levels monitored across cycles, and anti-therapeutic antibody incidence.
|
||||
References